Osamu Maeda

11PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmacogenomicsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 29, 2026
Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).

|May 21, 2026
Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

|Mar 08, 2026
FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito

|Jul 02, 2025
Pazopanib and antacids: insights from the WHO pharmacovigilance database.

Kazuki Nishida, Yao Liang, Osamu Maeda

|Jan 31, 2025
Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors.

Yao Liang, Osamu Maeda, Kazuki Nishida

|Feb 13, 2024
Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.

Osamu Maeda, Satoshi Furune, Mitsuro Kanda

Pageof 2

Frequent Collaborators

4 joint publications

Yuichi Ando

2 joint publications

Mitsuro Kanda

2 joint publications

Kazuki Nishida

2 joint publications

Yao Liang